NovoCure Ltd. (NVCR) PT Lowered to $62 at Piper Sandler
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Wall St futures mixed as Apple falls on margin warning, midterm results awaited
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts NVCR Hot Sheet
Price: $13.21 --0%
Rating Summary:
11 Buy, 5 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 15 | New: 12
Rating Summary:
11 Buy, 5 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 15 | New: 12
Join SI Premium – FREE
Piper Sandler analyst Jason Bednar lowered the price target on NovoCure Ltd. (NASDAQ: NVCR) to $62.00 (from $67.00) while maintaining a Neutral rating.
You May Also Be Interested In
- NovoCure Ltd. (NVCR) PT Lowered to $15 at Wells Fargo
- ON Semiconductor (ON) PT Lowered to $87 at Mizuho
- Insmed (INSM) PT Raised to $158 at Mizuho
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
